Endo Inc Stock Price, News & Analysis

Endo (OTCQX: NDOI) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before the market opens. The company will host a conference call at 8:00 a.m. ET on the same day.

Investors can access the audio webcast through the company's Investor Relations website at investor.endo.com. For those preferring a conference line, dial-in numbers are provided: 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (international). Participants should join 10 minutes before the start time. A webcast replay will be available after the event.

Mallinckrodt plc has secured a crucial ruling from the Irish High Court for its planned merger with Endo, Inc. (OTCQX: NDOI). This represents the final major legal hurdle for the stock and cash transaction, which is expected to close in early August 2025.

The merger, initially announced on March 13, 2025, aims to create a global therapeutics leader. Both companies' shareholders approved the deal last month. The combined entity will be headquartered in Dublin, Ireland, with Siggi Olafsson serving as President and CEO.

Post-merger, the companies plan to combine their generic pharmaceuticals and Endo's sterile injectables businesses, with a future intention to separate these operations from the combined company, subject to board approval.

Endo (NDOI) has completed the divestiture of its International Pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc. The total transaction value is up to $105 million, structured as $79 million paid at closing, $11 million in permitted holdbacks, and potential milestone payments of up to $15 million. The sale represents a significant strategic move for Endo, affecting its international market presence and financial position.

Mallinckrodt and Endo (NDOI) shareholders have approved a strategic merger to create a global pharmaceuticals leader through a stock and cash transaction. Following shareholder approval, Mallinckrodt will seek Irish High Court confirmation for the scheme of arrangement, with merger completion targeted for weeks after the July sanction hearing. The combined company will maintain headquarters in Dublin, Ireland, with Siggi Olafsson serving as President and CEO. Post-merger, the companies plan to combine their generic pharmaceuticals and Endo's sterile injectables businesses, with a future intention to separate these operations from the combined company, subject to Board approval. The merger aims to enhance product portfolios and create long-term value for stakeholders.

Mallinckrodt and Endo announced their planned leadership structure following their upcoming merger, scheduled for completion in H2 2025. The merged entity will create two distinct companies: a branded specialty pharmaceuticals company and Par Health, a spin-off focusing on generics and sterile injectables (GxSI). Siggi Olafsson, current Mallinckrodt CEO, will lead the merged company. The leadership team combines executives from both companies, including Tracy Basso (CHRO), Mark Bradley (Chief Integration Officer), Lisa French (CCO), and others. Stephen Welch, currently Head of Specialty Generics at Mallinckrodt, will become CEO of Par Health post-spin-off. The company is actively recruiting for key positions including CFO, Business Development & Strategy, and R&D leadership. The merger remains subject to shareholder approval and customary closing conditions.

Endo (OTCQX: NDOI) has launched a comprehensive Men's Health Month initiative for June 2025, focusing on raising awareness and education about men's health issues. The campaign targets underdiagnosed and stigmatized conditions including Peyronie's disease, erectile dysfunction, and testosterone deficiency. Key activities include digital outreach through social media, educational materials distribution in healthcare settings, email campaigns with clinical insights, and website content development. The company will participate in Wear Blue Day on June 13 to support men's health awareness. Justin Mattice, SVP & GM of Branded Specialty, emphasized the importance of empowering men to take an active role in their health management through proper information and awareness.

Endo (OTCQX: NDOI) has announced the launch of ADRENALIN® 8 mg/250 mL premixed bag, expanding its ready-to-use epinephrine product line. The product will begin shipping on May 19, 2025. ADRENALIN® holds the distinction of being the first FDA-approved and only commercially available manufacturer-prepared epinephrine premixed IV bag. The product offers key benefits including no compounding requirements, single-port IV tubing, and 24-month shelf life at room temperature. The company currently offers 4 mg/250 mL premixed bags and plans to launch 5 mg/250 mL and 10 mg/250 mL concentrations. ADRENALIN® is indicated for increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock.

Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.

The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.

Endo reported Q1 2025 financial results with total revenues of $393 million, down 6% from Q1 2024. XIAFLEX® revenues grew 7% to $121 million, driving Branded Pharmaceuticals segment growth. The company reported a net loss of $129 million, improved from $154 million loss in Q1 2024. Adjusted EBITDA decreased 32% to $99 million. Endo reaffirmed its 2025 guidance with expected revenues of $1,775-$1,860 million and adjusted EBITDA of $620-$650 million. Two major transactions were announced: a merger with Mallinckrodt where Endo shareholders will receive $80 million and own 49.9% of the combined company (expected to close in H2 2025), and the planned divestiture of its International Pharmaceuticals business (expected to close mid-2025).